Melanoma Clinical and Non-Clinical Studies, Key Companies, Therapeutic Assessment, Emerging Therapies, Treatment Algorithm, and Pipeline Analysis | IO Biotech, Moderna Inc., Merck Sharp & Dohme LLC, BioNTech SE, TILT Biotherapeutics LLC, Nykode Therapeuti

Melanoma Pipeline constitutes 150+ key companies continuously working towards developing 170+ Melanoma treatment therapies, analyzes DelveInsight.

Melanoma Overview:

Melanoma is a type of cancer that originates in melanocytes, the pigment-producing cells. In about 90% of cases, melanoma develops in the skin, but it can also affect the eyes, internal organs, and mucosal membranes of the gastrointestinal, respiratory, and urogenital tracts. It is the third most common skin cancer after basal cell carcinoma and squamous cell carcinoma and ranks as the fifth most common cancer in men and sixth in women. Despite its prevalence, melanoma has historically been difficult to treat, with drug development progressing slowly compared to other cancers.

Melanoma commonly spreads to the lymph nodes, lungs, liver, bones, and brain. Symptoms include unusual skin growths, changes in existing moles (such as increased size, darkening, irregular borders, or color variation), sores that do not heal, and skin lesions that become painful, itchy, or tender. Diagnosis typically involves a skin examination and the ABCDE method (evaluating asymmetry, border, color, diameter, and evolution of moles). If cancer is suspected, a biopsy is performed, which may be a punch biopsy (removing a round section of skin), excisional biopsy (removing the entire growth), or shave biopsy (shaving off the affected area). The tumor's thickness is assessed under a microscope, as thicker tumors carry a higher risk of spreading. Additional tests, such as imaging scans (CT, MRI, PET) and blood tests (including lactate dehydrogenase levels), help determine if the cancer has metastasized.

Melanoma treatment depends on the disease stage and the patient's overall health. In early stages, surgery can be curative. If the cancer spreads, lymph node removal (lymphadenectomy) may be necessary to prevent further metastasis. Metastasectomy is performed to eliminate small melanoma deposits in organs. Other treatments include targeted therapy, which attacks specific cancer cells, radiation therapy, and immunotherapy, which is widely used by biopharmaceutical companies to enhance the immune system's ability to fight melanoma.

Request for a detailed insights report on Melanoma pipeline insights @ https://www.delveinsight.com/report-store/melanoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

"Melanoma Pipeline Insight 2024" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Melanoma Therapeutics Market.

Key Takeaways from the Melanoma Pipeline Report

DelveInsight's Melanoma pipeline report depicts a robust space with 150+ active players working to develop 170+ pipeline therapies for Melanoma treatment.
Key Melanoma companies such as IO Biotech, Moderna Inc., Merck Sharp & Dohme LLC, BioNTech SE, TILT Biotherapeutics LLC, Nykode Therapeutics, Achilles Therapeutics UK Limited, Evaxion Biotech, InxMed, AiVita Biomedical, Cytovation AS, Ono Pharmaceuticals, Neon Therapeutics, Iovance Biotherapeutics, and others are evaluating new drugs for Melanoma to improve the treatment landscape.
Promising Melanoma pipeline therapies in various stages of development include IO102 IO103, mRNA 4157, MK-4830, BNT111, TILT 123, and others.

Recent breakthroughs in the Melanoma Pipeline Segment:
January 2025 - Ultimovacs ASA: A randomized, open-label study is being conducted to evaluate the efficacy and safety of UV1 vaccination in combination with nivolumab and ipilimumab as a first-line treatment for adult patients with histologically confirmed unresectable metastatic melanoma.

January 2025 - Regeneron Pharmaceuticals: This study is investigating the experimental drug fianlimab (REGN3767) in combination with cemiplimab (REGN2810), referred to as the "study drugs." The research focuses on melanoma patients and aims to assess the safety and effectiveness of fianlimab and cemiplimab compared to the approved combination of relatlimab and nivolumab, marketed as Opdualag™, for treating melanoma in both adults and children.

January 2025 - Amgen: This study aims to evaluate the efficacy, safety, and immunogenicity of ABP 206 in comparison with nivolumab in patients with treatment-naïve, unresectable, or metastatic melanoma. Participants will be randomly assigned (1:1) to receive either ABP 206 or nivolumab and will continue treatment until disease progression, unacceptable toxicity, or withdrawal of consent, for a maximum of 24 months. The total study duration for each participant is approximately 26 months.
In April 2024, Obsidian Therapeutics shared an update on its Phase I first-in-human trial of OBX-115 tumor-infiltrating lymphocyte (TIL) cell therapy for patients with advanced or metastatic melanoma. The update, presented at the American Association for Cancer Research (AACR) Annual Meeting in San Diego, CA, included safety data with a median follow-up of 25 weeks and newly detailed efficacy results.
In April 2024, Iovance Biotherapeutics announced that clinical data for lifileucel combined with pembrolizumab in frontline advanced melanoma, along with translational data, would be featured at the 2024 ASCO Annual Meeting.
Melanoma Pipeline Analysis
The report provides insights into:
The report provides detailed insights into the key companies that are developing therapies in the Melanoma Market.
The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Melanoma treatment.
It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
It navigates the emerging drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the Melanoma market.

Download our free sample page report on Melanoma pipeline insights @ https://www.delveinsight.com/sample-request/melanoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Melanoma Emerging Drugs

IO102 IO103 : IO Biotech
mRNA 4157: Moderna Inc.
MK-4830: Merck Sharp & Dohme LLC
BNT111: BioNTech SE
TILT 123: TILT Biotherapeutics LLC

Melanoma Companies

Around 150 key companies are actively developing therapies for colorectal cancer. Among them, IO Biotech has a melanoma drug candidate in the most advanced stage of development, specifically Phase III clinical trials.

DelveInsight's report covers around 170+ products under different phases of clinical development like

Late stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I) along with the details of
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates

Melanoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Intravenous
Subcutaneous
Oral
Intramuscular

Melanoma Products have been categorized under various Molecule types such as

Monoclonal antibody
Small molecule
Peptide

Download Sample Pages to Get an in-depth Assessment of the Emerging Melanoma Therapies and Key Companies: Melanoma Clinical Trials and advancements @ https://www.delveinsight.com/report-store/melanoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Melanoma Pipeline Therapeutic Assessment
• Melanoma Assessment by Product Type
• Melanoma By Stage
• Melanoma Assessment by Route of Administration
• Melanoma Assessment by Molecule Type

Download Melanoma Sample report to know in detail about the Melanoma treatment market @ Melanoma Therapeutic Assessment @ https://www.delveinsight.com/sample-request/melanoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Table of Content

1. Report Introduction
2. Executive Summary
3. Melanoma Current Treatment Patterns
4. Melanoma - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Melanoma Late-Stage Products (Phase-III)
7. Melanoma Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Melanoma Discontinued Products
13. Melanoma Product Profiles
14. Melanoma Key Companies
15. Melanoma Key Products
16. Dormant and Discontinued Products
17. Melanoma Unmet Needs
18. Melanoma Future Perspectives
19. Melanoma Analyst Review
20. Appendix
21. Report Methodology

Request the Sample PDF to Get Detailed Insights About the Melanoma Pipeline Reports Offerings: https://www.delveinsight.com/report-store/melanoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Contact Info:
Kritika Rehani
krehani@delveinsight.com
info@delveinsight.com
+14699457679

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

This release was published on openPR.